05:28 PM EDT, 07/15/2025 (MT Newswires) -- Repare Therapeutics ( RPTX ) said late Tuesday it has signed a global licensing agreement with Debiopharm International for its cancer drug candidate lunresertib.

Repare said it will get a $10 million upfront payment, and could earn up to $257 million in potential milestones from Debiopharm, a privately-owned, Swiss-based biopharmaceutical company.

"This agreement builds upon the success of Repare and Debiopharm's existing collaboration studying the combination of lunresertib and Debio 0123," said CEO Steve Forte.

Shares of Repare were up more than 13% in after-hours activity.